What Is AstraZeneca - Search News

AstraZeneca, Bristol Myers

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

UK pharmaceutical company AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, according to a report by the Financial Times.

· 1d

AstraZeneca, Bristol Myers Squibb To Merge? Let's Consider The Pros And Cons

· 1d · on MSN

AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports

· 1d

AstraZeneca slides Monday, underperforms market

AstraZeneca PLC closed 26.90% below its 52-week high of £157.32, which the company achieved on February 18th.

· 1d

A $400 Billion AstraZeneca Deal Could Get Messy

· 15h

FTSE 100 dips as AstraZeneca slides on Bristol Myers tie-up talks

· 1d

AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

Shares in AstraZeneca closed down some 9%, the ‌biggest drop since 2020, as investors and analysts said Britain's biggest drugmaker had little need for a transformative acquisition despite potential c...

· 2d

AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger

· 1d

AstraZeneca’s US tilt could be the death knell for London’s stock market

15h

AstraZeneca-BMY megadeal talk sparks huge market rift

Two of the world's biggest drugmakers moved in opposite directions on Monday, and the split says a lot about how Wall Street reads a merger. Reports surfaced over the weekend that AstraZeneca (AZN) had held talks about combining with Bristol Myers Squibb (BMY).

Nasdaq

AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?

AstraZeneca AZN is scheduled to report fourth-quarter and full-year 2025 results on Feb. 10, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 4.39% The Zacks Consensus Estimate for quarterly sales is ...

AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks

AstraZeneca delivered solid core EPS growth of 18% YoY, while revenue growth came in line with expectations for the full year 2026. Read more on AZN stock here.

AOL

Is AstraZeneca Stock a Buy?

U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country -- as well as several other top executives -- were arrested ...